var data={"title":"Neonatal herpes simplex virus infection: Management and prevention","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Neonatal herpes simplex virus infection: Management and prevention</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/contributors\" class=\"contributor contributor_credentials\">Gail J Demmler-Harrison, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/contributors\" class=\"contributor contributor_credentials\">Sheldon L Kaplan, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/contributors\" class=\"contributor contributor_credentials\">Leonard E Weisman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/contributors\" class=\"contributor contributor_credentials\">Carrie Armsby, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Aug 29, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neonatal infection with herpes simplex virus (HSV) occurs in 1 out of every 3200 to 10,000 live births, causes serious morbidity and mortality, and leaves many survivors with permanent sequelae [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/1-4\" class=\"abstract_t\">1-4</a>]. Despite this seemingly low prevalence, neonatal HSV accounts for 0.2 percent of neonatal hospitalizations and 0.6 percent of in-hospital neonatal deaths in the United States, and is associated with substantial healthcare resource utilization [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/5-8\" class=\"abstract_t\">5-8</a>].</p><p>The management and prevention of neonatal HSV infection will be reviewed here. The clinical features and diagnosis of neonatal HSV infection and non-neonatal herpes simplex virus infection are discussed separately:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=neonatal-herpes-simplex-virus-infection-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Neonatal herpes simplex virus infection: Clinical features and diagnosis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=genital-herpes-simplex-virus-infection-and-pregnancy\" class=\"medical medical_review\">&quot;Genital herpes simplex virus infection and pregnancy&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=herpetic-gingivostomatitis-in-young-children\" class=\"medical medical_review\">&quot;Herpetic gingivostomatitis in young children&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-herpes-simplex-virus-type-1-infection\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of herpes simplex virus type 1 infection&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">OVERVIEW</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The treatment of neonatal herpes simplex virus (HSV) infection involves supportive measures and antiviral therapy.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Supportive measures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Supportive measures for the critically ill neonate with disseminated or central nervous system (CNS) disease include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fluid and electrolyte maintenance and avoidance of hypoglycemia. (See <a href=\"topic.htm?path=fluid-and-electrolyte-therapy-in-newborns\" class=\"medical medical_review\">&quot;Fluid and electrolyte therapy in newborns&quot;</a> and <a href=\"topic.htm?path=management-and-outcome-of-neonatal-hypoglycemia\" class=\"medical medical_review\">&quot;Management and outcome of neonatal hypoglycemia&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Management of shock and systemic inflammatory response. (See <a href=\"topic.htm?path=septic-shock-in-children-rapid-recognition-and-initial-resuscitation-first-hour\" class=\"medical medical_review\">&quot;Septic shock in children: Rapid recognition and initial resuscitation (first hour)&quot;</a> and <a href=\"topic.htm?path=septic-shock-in-children-ongoing-management-after-resuscitation\" class=\"medical medical_review\">&quot;Septic shock in children: Ongoing management after resuscitation&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Provision of oxygen and mechanical ventilator support. (See <a href=\"topic.htm?path=noninvasive-oxygen-delivery-and-oxygen-monitoring-in-the-newborn\" class=\"medical medical_review\">&quot;Noninvasive oxygen delivery and oxygen monitoring in the newborn&quot;</a> and <a href=\"topic.htm?path=mechanical-ventilation-in-neonates\" class=\"medical medical_review\">&quot;Mechanical ventilation in neonates&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nutritional support. (See <a href=\"topic.htm?path=overview-of-enteral-nutrition-in-infants-and-children\" class=\"medical medical_review\">&quot;Overview of enteral nutrition in infants and children&quot;</a> and <a href=\"topic.htm?path=parenteral-nutrition-in-infants-and-children\" class=\"medical medical_review\">&quot;Parenteral nutrition in infants and children&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Control of seizures. (See <a href=\"topic.htm?path=treatment-of-neonatal-seizures\" class=\"medical medical_review\">&quot;Treatment of neonatal seizures&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Management of disseminated intravascular coagulation, including fresh frozen plasma <span class=\"nowrap\">and/or</span> platelet transfusions in patients with significant bleeding. (See <a href=\"topic.htm?path=disseminated-intravascular-coagulation-in-infants-and-children#H29\" class=\"medical medical_review\">&quot;Disseminated intravascular coagulation in infants and children&quot;, section on 'Treatment'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antimicrobial treatment for secondary bacterial infections, especially for gram negative organisms in neonates with ascites and liver necrosis. (See <a href=\"topic.htm?path=management-and-outcome-of-sepsis-in-term-and-late-preterm-infants#H3\" class=\"medical medical_review\">&quot;Management and outcome of sepsis in term and late preterm infants&quot;, section on 'Antibiotic therapy'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information\" class=\"drug drug_pediatric\">immune globulin</a>, especially if myocardial <span class=\"nowrap\">dysfunction/myocarditis</span> or systemic inflammatory response is present [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/9\" class=\"abstract_t\">9</a>]. (See <a href=\"topic.htm?path=treatment-and-prognosis-of-myocarditis-in-children#H7\" class=\"medical medical_review\">&quot;Treatment and prognosis of myocarditis in children&quot;, section on 'Intravenous immunoglobulin'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other interventions, such as glucocorticoids, exchange transfusion, and liver transplantation have been reported in case reports [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/9-12\" class=\"abstract_t\">9-12</a>].</p><p/><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">ACYCLOVIR THERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We recommend <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> as the antiviral agent of choice for the treatment of all categories of neonatal herpes simplex virus (HSV) infections, including skin, eye, mouth (SEM), central nervous system (CNS), and disseminated disease (<a href=\"image.htm?imageKey=PEDS%2F106132\" class=\"graphic graphic_table graphicRef106132 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/13-16\" class=\"abstract_t\">13-16</a>]. (See <a href=\"topic.htm?path=neonatal-herpes-simplex-virus-infection-clinical-features-and-diagnosis#H6\" class=\"medical medical_review\">&quot;Neonatal herpes simplex virus infection: Clinical features and diagnosis&quot;, section on 'Neonatal HSV'</a>.)</p><p>Treatment of neonatal HSV disease with antiviral therapy improves survival and outcome, especially if treatment is begun early in the course of illness [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/14,15,17\" class=\"abstract_t\">14,15,17</a>]. Before antiviral therapy was available, the one-year mortality rates for neonates with disseminated and CNS HSV disease were 85 and 50 percent, respectively [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/18\" class=\"abstract_t\">18</a>]. With the advent of antiviral therapy, mortality rates declined to 29 and 4 percent, respectively [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/14,15,19\" class=\"abstract_t\">14,15,19</a>].</p><p>Antiviral therapy also has increased the proportion of survivors of disseminated disease who have normal neurologic development (from 50 to approximately 80 percent) [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/14,18,19\" class=\"abstract_t\">14,18,19</a>]. Antiviral therapy does not appear to have affected the proportion of survivors of CNS disease with normal neurologic development (approximately 30 percent both before and after antiviral therapy became available) [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/14,18,19\" class=\"abstract_t\">14,18,19</a>].</p><p>Early antiviral treatment of infants with SEM disease prevents progression to CNS or disseminated disease [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/20\" class=\"abstract_t\">20</a>]. Between 50 and 60 percent of infants with SEM who do not receive antiviral therapy progress to CNS or disseminated disease.</p><p>In a randomized controlled trial, the morbidity and mortality were similar among infants treated with <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> and vidarabine [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/15\" class=\"abstract_t\">15</a>]. However, vidarabine has systemic toxicity and a dosing schedule that requires 12-hour infusions.</p><p>The mechanism of action, pharmacokinetics, and toxicity of <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> are discussed separately. (See <a href=\"topic.htm?path=acyclovir-an-overview\" class=\"medical medical_review\">&quot;Acyclovir: An overview&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Indications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Indications for <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> therapy include [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/13,21-23\" class=\"abstract_t\">13,21-23</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Virologically proven HSV disease. (See <a href=\"topic.htm?path=neonatal-herpes-simplex-virus-infection-clinical-features-and-diagnosis#H67759361\" class=\"medical medical_review\">&quot;Neonatal herpes simplex virus infection: Clinical features and diagnosis&quot;, section on 'Detection of HSV'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinically suspected HSV disease (<a href=\"image.htm?imageKey=PEDS%2F67814\" class=\"graphic graphic_figure graphicRef67814 \">figure 1</a>), pending viral studies. (See <a href=\"topic.htm?path=neonatal-herpes-simplex-virus-infection-clinical-features-and-diagnosis#H4\" class=\"medical medical_review\">&quot;Neonatal herpes simplex virus infection: Clinical features and diagnosis&quot;, section on 'Clinical manifestations'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Asymptomatic but at risk due to exposure (maternal active genital lesions) (<a href=\"image.htm?imageKey=PEDS%2F106124\" class=\"graphic graphic_algorithm graphicRef106124 \">algorithm 1</a>). (See <a href=\"#H24\" class=\"local\">'Management of the asymptomatic exposed infant'</a> below.)</p><p/><p>The indications for initiation of empiric <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> are not standardized. Most experts agree that empiric acyclovir is indicated for neonates with clinical features suggestive of HSV infection, which include mucocutaneous vesicles (<a href=\"image.htm?imageKey=PEDS%2F75059%7EPEDS%2F56041%7EPEDS%2F78598\" class=\"graphic graphic_picture graphicRef75059 graphicRef56041 graphicRef78598 \">picture 1A-C</a>), seizures, lethargy, respiratory distress, thrombocytopenia, coagulopathy, blood oozing from intravascular catheter sites, hypothermia, sepsis-like illness, hepatomegaly, ascites, or markedly elevated transaminases (<a href=\"image.htm?imageKey=PEDS%2F67814\" class=\"graphic graphic_figure graphicRef67814 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/13,21-23\" class=\"abstract_t\">13,21-23</a>]. Many experts recommend empiric treatment for ill-appearing neonates with fever or aseptic meningitis until results of HSV workup are known. However, expert opinions differ regarding the relative benefits, risks, and cost-effectiveness of empiric acyclovir before virologic confirmation in other clinical situations (eg, cerebrospinal fluid [CSF] pleocytosis with a predominance of mononuclear cells in an otherwise well-appearing infant, persistent or recurrent erythema or <span class=\"nowrap\">purulence/crusting</span> at the site of a scalp electrode, fever without localizing signs in an infant &le;21 days of age, etc) [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/21-24\" class=\"abstract_t\">21-24</a>]. (See <a href=\"topic.htm?path=neonatal-herpes-simplex-virus-infection-clinical-features-and-diagnosis#H4\" class=\"medical medical_review\">&quot;Neonatal herpes simplex virus infection: Clinical features and diagnosis&quot;, section on 'Clinical manifestations'</a>.)</p><p>The full course of <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> therapy should be administered for infants with positive HSV cultures or deoxyribonucleic acid (DNA) polymerase chain reaction (PCR), and infants with negative virologic studies in whom neonatal HSV is strongly suspected. (See <a href=\"#H8\" class=\"local\">'Duration of therapy'</a> below.)</p><p class=\"headingAnchor\" id=\"H67765302\"><span class=\"h2\">Timing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intravenous (IV) <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> should be administered at the time the diagnosis of neonatal HSV is <strong>suspected</strong>. Prompt administration improves outcome [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/5,14,15,17,25\" class=\"abstract_t\">5,14,15,17,25</a>]. Acyclovir therapy should be continued while clinical observation and results of laboratory and imaging evaluations are completed.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Pretreatment evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A comprehensive laboratory evaluation for HSV should be performed before initiation of <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> therapy. The evaluation should include (if the infant is clinically stable enough to undergo it) [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/13,19\" class=\"abstract_t\">13,19</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Testing to detect HSV, including <strong>all</strong> of the following (see <a href=\"topic.htm?path=neonatal-herpes-simplex-virus-infection-clinical-features-and-diagnosis#H67760522\" class=\"medical medical_review\">&quot;Neonatal herpes simplex virus infection: Clinical features and diagnosis&quot;, section on 'Specimens to collect'</a>):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Surface cultures from the conjunctivae, mouth, nasopharynx, and rectum</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Viral culture of <span class=\"nowrap\">swabs/scrapings</span> of skin and mucous membrane lesions, if present; direct immunofluorescence assay (DFA) may be used in addition to viral culture to permit rapid detection</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>CSF HSV PCR</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Whole blood or plasma HSV PCR</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Viral culture of other specimens that are readily available (eg, tracheal aspirates in intubated patients)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Testing to determine the degree of organ involvement and studies to exclude other diseases that may cause similar symptoms (see <a href=\"topic.htm?path=neonatal-herpes-simplex-virus-infection-clinical-features-and-diagnosis#H67759355\" class=\"medical medical_review\">&quot;Neonatal herpes simplex virus infection: Clinical features and diagnosis&quot;, section on 'Additional studies'</a>): </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Complete blood count (CBC), including differential and platelet count</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Liver transaminases, total and direct bilirubin, ammonia (ammonia should be performed to exclude liver failure and metabolic disease in neonates with elevated liver enzymes and fulminant sepsis, but is not necessary for all neonates with suspected HSV)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Blood urea nitrogen (BUN), creatinine, and urinalysis (to assess renal function and hydration status)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>CSF cell count and differential, glucose, protein</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Ophthalmologic examination</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Neuroimaging (see <a href=\"topic.htm?path=neonatal-herpes-simplex-virus-infection-clinical-features-and-diagnosis#H21\" class=\"medical medical_review\">&quot;Neonatal herpes simplex virus infection: Clinical features and diagnosis&quot;, section on 'Brain imaging'</a>)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Electroencephalogram (EEG) in neonates suspected to have CNS disease (see <a href=\"topic.htm?path=neonatal-herpes-simplex-virus-infection-clinical-features-and-diagnosis#H19\" class=\"medical medical_review\">&quot;Neonatal herpes simplex virus infection: Clinical features and diagnosis&quot;, section on 'Electroencephalogram'</a>)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Chest radiograph, for neonates with respiratory distress</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Blood and CSF cultures to evaluate for bacterial sepsis </p><p/><p class=\"headingAnchor\" id=\"H443693524\"><span class=\"h2\">Initial treatment</span></p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h3\">Dose</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The dose of <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> for all forms of neonatal HSV is 60 <span class=\"nowrap\">mg/kg</span> per day intravenously divided every eight hours [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/14\" class=\"abstract_t\">14</a>]. The dose of acyclovir must be adjusted for neonates with renal impairment.</p><p>The benefits of this dose compared with standard-dose <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> 30 <span class=\"nowrap\">mg/kg</span> per day were established in an open-label study in which 72 neonates with CNS or disseminated HSV were treated with acyclovir 60 <span class=\"nowrap\">mg/kg</span> per day for 21 days [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/14\" class=\"abstract_t\">14</a>]. Their outcomes were compared with those of infants in an earlier trial who were treated with acyclovir 30 <span class=\"nowrap\">mg/kg</span> per day for 10 days [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/15\" class=\"abstract_t\">15</a>]. The higher dose was associated with increased survival at 24 months (odds ratio [OR] 3.3, 95% CI 1.5-7.3).</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h3\">Duration of therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The duration of <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> therapy for neonatal HSV infection depends upon the pattern of illness and response to therapy [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/5,13,14,16\" class=\"abstract_t\">5,13,14,16</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Skin, eye, and mouth disease</strong> - Localized skin, eye, and mouth (SEM) disease should be treated for a minimum of 14 days if disseminated and CNS disease have been excluded (<a href=\"image.htm?imageKey=PEDS%2F106132\" class=\"graphic graphic_table graphicRef106132 \">table 1</a>). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Disseminated and CNS disease</strong> - Disseminated and CNS disease should be treated for a <strong>minimum</strong> of 21 days. Because the persistence of HSV DNA in the CSF is associated with poor outcome, lumbar puncture should be repeated near the end of therapy to ensure that CSF HSV PCR is negative [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/5,13,19,26-29\" class=\"abstract_t\">5,13,19,26-29</a>].</p><p/><p class=\"bulletIndent1\">For infants with persistently positive CSF HSV PCR despite 21 days of <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> therapy, antiviral treatment is continued and CSF HSV PCR testing is repeated weekly until negative [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/13,19\" class=\"abstract_t\">13,19</a>]. Consultation with a pediatric infectious disease specialist is warranted in cases of persistently positive CSF or blood HSV PCR. The clinical significance of persistently positive blood PCR is uncertain. Data from a small cohort of infants (n = 6) with disseminated HSV disease who were monitored with serial plasma HSV PCR levels during treatment suggest that acyclovir therapy has a uniform and predictable effect on plasma HSV level regardless of the baseline viral level and that this monitoring can be used to help guide duration of therapy [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/30\" class=\"abstract_t\">30</a>]. In our practice, we repeat the blood HSV PCR at the end of the 21-day treatment course to assess for viremia clearance. If the blood HSV PCR is persistently positive, additional IV acyclovir therapy <span class=\"nowrap\">and/or</span> evaluation for primary immune disorder is undertaken. </p><p/><p class=\"headingAnchor\" id=\"H10\"><span class=\"h3\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Systemic <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> therapy is well tolerated by most neonates and side effects are unusual. Potential adverse effects include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Kidney injury caused by crystallization in the renal tubules, which is more likely to occur if the neonate is dehydrated</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dose-dependent reversible neutropenia [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/5,14,19\" class=\"abstract_t\">5,14,19</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ulceration at the site of peripheral extravasation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Seizures, especially if the dose is not adjusted in patients with renal impairment</p><p/><p class=\"headingAnchor\" id=\"H443693633\"><span class=\"h3\">Monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Routine monitoring for neonates receiving IV <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> includes the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Renal function</strong> &ndash; BUN and creatinine are monitored once or twice weekly, depending on the clinical status of the patient. For patients with acute kidney injury <span class=\"nowrap\">and/or</span> severe disseminated HSV disease, BUN and creatinine should be monitored daily. In addition, the infant's hydration status should be monitored by assessing intake and output and measuring urine specific gravity. In our practice, we aim to keep urine specific gravity &lt;1.010 during <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> therapy to reduce renal toxicity. The acyclovir dose should be adjusted if creatinine clearance is lower than expected for age of patient.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Absolute neutrophil count</strong> &ndash; Absolute neutrophil count (ANC) should be followed approximately twice per week during the course of therapy [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/14,19\" class=\"abstract_t\">14,19</a>]. The <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> dosage should be reduced or granulocyte colony-stimulating factor should be administered if the ANC remains <span class=\"nowrap\">&lt;500/microL</span> for an extended period of time without an alternative explanation for the neutropenia.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Infusion site</strong> &ndash; Monitoring of the local infusion site is important because local infiltration can cause superficial or deep ulcerative lesions. If possible, administration through central access or a peripherally-inserted central catheter (PICC) is preferred.</p><p/><p class=\"headingAnchor\" id=\"H67767244\"><span class=\"h3\">IV acyclovir not available</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>If intravenous (IV) <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> is not available, in agreement with the American Academy of Pediatrics (AAP) Committee on Infectious Diseases, we suggest IV <a href=\"topic.htm?path=ganciclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">ganciclovir</a> as a first-line alternative [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/31-33\" class=\"abstract_t\">31-33</a>]; the dose is 6 <span class=\"nowrap\">mg/kg</span> every 12 hours IV for infants &le;90 days of age and 5 <span class=\"nowrap\">mg/kg</span> every 12 hours IV for infants &gt;90 days. We suggest IV <a href=\"topic.htm?path=foscarnet-pediatric-drug-information\" class=\"drug drug_pediatric\">foscarnet</a> as a second-line alternative; the dose is 60 <span class=\"nowrap\">mg/kg</span> every 12 hours IV.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Oral suppressive therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Following parenteral treatment for all forms of neonatal HSV disease (SEM, CNS, and disseminated disease) (<a href=\"image.htm?imageKey=PEDS%2F106132\" class=\"graphic graphic_table graphicRef106132 \">table 1</a>), we suggest suppressive therapy with oral <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> 300 <span class=\"nowrap\">mg/m<sup>2</sup></span> per dose three times per day for six months; the dose should be adjusted each month to account for growth [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/13,29,34\" class=\"abstract_t\">13,29,34</a>]. This recommendation is based on evidence that suppressive therapy reduces cutaneous recurrences and is associated with improved neurologic outcomes in infants with CNS disease [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/34\" class=\"abstract_t\">34</a>].</p><p><a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">Acyclovir</a> is preferred to <a href=\"topic.htm?path=valacyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">valacyclovir</a> because the safety and efficacy of valacyclovir have not been established in infants younger than two years of age. Furthermore, since only tablet form is available, an extemporaneously compounded valacyclovir oral suspension (25 to 50 <span class=\"nowrap\">mg/mL)</span> must be specially prepared for infants [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/35\" class=\"abstract_t\">35</a>]. Based on limited data on the pharmacokinetics and safety of valacyclovir in pediatric patients, doses of 10 to 20 <span class=\"nowrap\">mg/kg</span> of extemporaneously compounded valacyclovir oral suspension, administered twice daily, produce favorable acyclovir blood concentrations and appear well tolerated in most children [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/36,37\" class=\"abstract_t\">36,37</a>].</p><p>The effectiveness of long-term suppression with oral <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> in reducing the risk of CNS recurrence after neonatal HSV disease is unknown. CNS recurrence in neonates receiving long-term oral suppression has been documented [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/38\" class=\"abstract_t\">38</a>]. Nonetheless, oral acyclovir suppression appears to be associated with improved neurodevelopmental outcome. In a multicenter trial, 74 infants (45 with CNS HSV disease, 29 with SEM HSV disease) were randomly assigned to oral acyclovir 300 <span class=\"nowrap\">mg/m2</span> per dose three times per day or placebo immediately following parenteral acyclovir treatment [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/34\" class=\"abstract_t\">34</a>]. In children with CNS involvement, acyclovir suppression was associated with higher mean infant development scores at 12 months of age (88 versus 68 on the Bayley Scales of Infant Development, 2<sup>nd</sup> edition in which scores range from 50 to 150). The incidence and degree of neutropenia were similar in the treatment and placebo groups. </p><p>Adverse effects of oral <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> suppression may include dose-dependent reversible neutropenia (in one-half to two-thirds of infants in previous studies) and emergence of HSV mutants that are acyclovir resistant [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/5,19,38,39\" class=\"abstract_t\">5,19,38,39</a>]. We monitor the ANC monthly in neonates receiving oral suppressive therapy. (See <a href=\"#H443693633\" class=\"local\">'Monitoring'</a> above.)</p><p>We suggest oral <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> suppressive therapy for six months immediately following parenteral acyclovir for neonatal HSV disease, including SEM, CNS, and disseminated HSV disease [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/29,34\" class=\"abstract_t\">29,34</a>].</p><p class=\"headingAnchor\" id=\"H443693101\"><span class=\"h2\">Treatment of recurrences</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal management of cutaneous recurrence is not established. However, treatment doses of oral <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> (10 to 20 <span class=\"nowrap\">mg/kg</span> per dose three times per day for young infants, or 10 to 15 <span class=\"nowrap\">mg/kg</span> per dose four to five times per day for older infants and children) may be administered early at the time of each cutaneous recurrence to reduce the discomfort and shedding associated with the lesions, or preemptively, for a brief period of one to two weeks, when a cutaneous recurrence is anticipated, such as times of high stress or exposure to sunlight.</p><p>In patients with frequent cutaneous recurrences that are painful or disruptive to daily life, long-term oral suppression may be of benefit. There is a broad range of acceptable doses. The author of this topic review generally prefers <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> 20 <span class=\"nowrap\">mg/kg</span> per dose twice per day, but in some patients, 10 <span class=\"nowrap\">mg/kg</span> per dose twice per day is effective. Suppression may be discontinued, and the patient observed, if no cutaneous recurrences are documented after a 12-month period.</p><p>An increase of the dosing frequency to three or four times daily for a brief period of time may be of benefit if a recurrence &quot;breaks through&quot; twice-daily oral suppression. HSV lesions that occur while the patient is receiving <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> three to four times per day should be cultured and the HSV isolate tested for acyclovir resistance.</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Treatment of eye disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neonates with ocular HSV involvement, such as keratitis, should receive a topical ophthalmic solution (eg, 1 percent <a href=\"topic.htm?path=trifluridine-pediatric-drug-information\" class=\"drug drug_pediatric\">trifluridine</a>, 0.1 percent idoxuridine [iododeoxyuridine], or 0.15 percent <a href=\"topic.htm?path=ganciclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">ganciclovir</a>) in addition to systemic <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> therapy [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/13\" class=\"abstract_t\">13</a>]. They should also be referred to an ophthalmologist for consultation.</p><p>Long-term suppressive therapy with oral <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> (300 <span class=\"nowrap\">mg/m<sup>2</sup></span> per dose three times per day or 10 to 20 <span class=\"nowrap\">mg/kg</span> per dose three times per day) may be warranted for patients with HSV involvement of the eye if there is a risk of impaired vision with reactivation [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/5,19,29\" class=\"abstract_t\">5,19,29</a>]. (See <a href=\"#H11\" class=\"local\">'Oral suppressive therapy'</a> above.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">OUTCOME</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The outcome of neonatal herpes simplex virus (HSV) disease depends upon the clinical pattern. HSV infection is lifelong, even with appropriate therapy. Recurrence of mucocutaneous lesions, eye disease, <span class=\"nowrap\">and/or</span> central nervous system (CNS) disease may occur.</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Disseminated disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The one-year mortality rate for disseminated disease is 29 percent [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/14\" class=\"abstract_t\">14</a>]. The risk of mortality is increased in infants with lethargy, severe hepatitis, acute liver failure, coma or near-coma at the time of presentation, disseminated intravascular coagulopathy, prematurity, and pneumonitis [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/19,40,41\" class=\"abstract_t\">19,40,41</a>].</p><p>Approximately 80 percent of survivors of disseminated neonatal HSV disease may have normal neurologic development [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/14,18,19\" class=\"abstract_t\">14,18,19</a>]. The risk of neurodevelopmental abnormalities (eg, developmental delay, hemiparesis, persistent seizures, microcephaly, blindness) is increased among infants with seizures at or before the initiation of antiviral therapy [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/19\" class=\"abstract_t\">19</a>].</p><p>Severe hepatitis, caused by either HSV-1 or -2, may cause potentially fatal, acute liver failure in neonates with disseminated disease. Liver transplantation has been carried out successfully in a few reported neonates with fulminant hepatic failure associated with disseminated neonatal HSV disease [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/10,42,43\" class=\"abstract_t\">10,42,43</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">CNS disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The one-year mortality rate for CNS disease is 4 percent [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/14\" class=\"abstract_t\">14</a>]. Prematurity, seizures, and coma or near-coma at the time of presentation are associated with increased risk of mortality in CNS disease [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/19,40,41\" class=\"abstract_t\">19,40,41</a>].</p><p>Approximately 30 percent of survivors of neonatal CNS HSV have normal neurologic development [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/14,18,19\" class=\"abstract_t\">14,18,19</a>]. The risk of neurodevelopmental abnormalities is increased among infants with seizures at or before the initiation of antiviral therapy [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/19\" class=\"abstract_t\">19</a>].</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Skin, eye, and mouth disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mortality is rare in neonatal HSV disease that is localized to the skin, eye, and mouth (SEM; in whom disseminated and CNS disease have been appropriately excluded). Less than 2 percent of <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> recipients have developmental delay after recovery from neonatal SEM HSV disease [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/14,15,19\" class=\"abstract_t\">14,15,19</a>]. The risk of neurodevelopmental abnormalities is increased in infants with &ge;3 recurrences of skin lesions before six months of age [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/41\" class=\"abstract_t\">41</a>]. Patients with ocular involvement are at risk for long-term complications, including vision loss, and require close follow-up. (See <a href=\"#H20\" class=\"local\">'Long-term follow-up'</a> below.)</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h2\">Cutaneous recurrence</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Even after successful parenteral treatment, recurrence of HSV can occur and may be a lifelong problem for the patient and family. Fortunately, recurrence of CNS disease is rare [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/38,39\" class=\"abstract_t\">38,39</a>]. However, recurrent vesicles at sites in the skin, eyes, and mouth (SEM) are common and occur in 50 to 80 percent of neonates, with 1 to 12 episodes in the first year of life [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/13\" class=\"abstract_t\">13</a>]. Infants with &ge;3 cutaneous recurrences during the first six months of life are at increased risk of neurodevelopmental abnormalities at follow-up [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/41\" class=\"abstract_t\">41</a>]. Recurrence of skin lesions may affect child care arrangements and is disruptive to the lives of patients and their families [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/19\" class=\"abstract_t\">19</a>].</p><p>Because the risk of recurrence in survivors of neonatal HSV disease is high, long-term suppressive therapy with oral <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> is recommended to reduce skin or eye recurrences during infancy [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"#H11\" class=\"local\">'Oral suppressive therapy'</a> above.)</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h1\">LONG-TERM FOLLOW-UP</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Survivors of neonatal herpes simplex virus (HSV) infection, especially infants with involvement of the central nervous system (CNS), should be followed closely for achievement of developmental milestones [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/19\" class=\"abstract_t\">19</a>]. They should undergo formal neurodevelopmental assessments as indicated. Referral to early intervention programs (eg, physical therapy, occupational therapy, speech therapy) should be made at the earliest sign of potential impairment. (See <a href=\"topic.htm?path=developmental-behavioral-surveillance-and-screening-in-primary-care#H3577452445\" class=\"medical medical_review\">&quot;Developmental-behavioral surveillance and screening in primary care&quot;, section on 'Follow-up'</a>.)</p><p>Audiologic assessments are usually recommended as well. However, evidence suggests that the incidence of hearing loss after neonatal HSV disease is low [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/44\" class=\"abstract_t\">44</a>]. (See <a href=\"topic.htm?path=hearing-impairment-in-children-evaluation\" class=\"medical medical_review\">&quot;Hearing impairment in children: Evaluation&quot;</a>.)</p><p>Patients with eye disease require careful follow-up with an ophthalmologist. Late onset recurrences have been documented [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/45,46\" class=\"abstract_t\">45,46</a>]. The family should be counseled to seek medical care promptly if symptoms of eye disease recur.</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h1\">PREVENTION</span></p><p class=\"headingAnchor\" id=\"H22\"><span class=\"h2\">General measures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Strategies for prevention of intrauterine and perinatally acquired herpes simplex virus (HSV) infection, including identification of high-risk pregnant women, cesarean delivery, maternal antiviral therapy, and anticipatory guidance for pregnant women and partners, are discussed separately. (See <a href=\"topic.htm?path=genital-herpes-simplex-virus-infection-and-pregnancy#H35\" class=\"medical medical_review\">&quot;Genital herpes simplex virus infection and pregnancy&quot;, section on 'Screening pregnant women with no HSV history'</a>.)</p><p>Postnatal transmission of HSV can be prevented by counseling family members with active HSV lesions (cold sores, herpetic whitlow, herpetic gingivostomatitis) or a history of cold sores or HSV lesions in the recent past to avoid close contact with and avoid kissing the newborn infant. Women with herpetic breast lesions should not breastfeed from the affected breast until the lesions have resolved because direct contact with the lesions may transmit the HSV to the infant [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/47\" class=\"abstract_t\">47</a>]. Mothers should use careful hand hygiene and cover any lesions with which the infant might come into contact.</p><p>Infants born to women with <strong>active HSV lesions</strong> should be managed with contact precautions during hospitalization, with a private room, or while rooming with the mother [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/13\" class=\"abstract_t\">13</a>]. Some experts suggest that contact precautions are not necessary for such infants who are born by cesarean delivery &lt;4 hours after rupture of membranes. Contact precautions are not necessary for infants born to women with a history of <strong>recurrent</strong> genital HSV who have no genital lesions at the time of delivery.</p><p>Contact precautions also should be used for infants who are hospitalized with HSV infection if they have mucocutaneous lesions [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/13\" class=\"abstract_t\">13</a>]. The median duration of viral shedding from skin vesicles and mucosal lesions in infants receiving <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> therapy is five to eight days [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/14\" class=\"abstract_t\">14</a>]. However, contact precautions may be continued for a longer period of time if the patient is hospitalized. (See <a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection#H954996324\" class=\"medical medical_review\">&quot;Infection prevention: Precautions for preventing transmission of infection&quot;, section on 'Contact precautions'</a>.)</p><p>Infants and children with cutaneous recurrence of neonatal HSV should be counseled to cover the lesions to prevent potential transmission through direct contact [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/48\" class=\"abstract_t\">48</a>].</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h2\">Vaccine</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no licensed, effective vaccine against HSV-1 or HSV-2 infection. However, a candidate HSV-2 gD subunit vaccine is in phase III clinical trials [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/5,49\" class=\"abstract_t\">5,49</a>].</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h1\">MANAGEMENT OF THE ASYMPTOMATIC EXPOSED INFANT</span></p><p class=\"headingAnchor\" id=\"H421546997\"><span class=\"h2\">Overview</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal management of asymptomatic infants who are exposed to maternal herpes simplex virus (HSV) at delivery (as documented by maternal virologic testing or active genital lesions [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/16\" class=\"abstract_t\">16</a>]) has not been evaluated in controlled trials [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/29\" class=\"abstract_t\">29</a>]. However, experts and expert groups provide some guidelines regarding the need for cultures and prophylactic or anticipatory antiviral therapy based upon the risk of transmission under various circumstances (<a href=\"image.htm?imageKey=PEDS%2F106124\" class=\"graphic graphic_algorithm graphicRef106124 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/13,16,50-54\" class=\"abstract_t\">13,16,50-54</a>]. Consultation with a pediatric infectious diseases specialist is suggested for guidance in difficult clinical situations.</p><p>The risk of transmission to the infant depends upon a number of factors, including (see <a href=\"topic.htm?path=genital-herpes-simplex-virus-infection-and-pregnancy#H13\" class=\"medical medical_review\">&quot;Genital herpes simplex virus infection and pregnancy&quot;, section on 'Vertical transmission'</a>) [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/54\" class=\"abstract_t\">54</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Whether the maternal infection is primary or recurrent (the risk is highest with primary infection)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Maternal HSV antibody status</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Duration of rupture of membranes</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The integrity of mucocutaneous barriers (eg, the use of fetal scalp electrodes)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cesarean versus vaginal delivery</p><p/><p>The risk of transmission is greatest (25 to 60 percent) among infants delivered vaginally or &ge;4 hours after rupture of membranes to mothers with active genital lesions and no history of HSV infection [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/1,13,29,54\" class=\"abstract_t\">1,13,29,54</a>]. The risk of transmission is lower (&lt;2 percent) for infants delivered vaginally or &ge;4 hours after rupture of membranes to mothers with recurrent HSV infection and active genital lesions. The risk of transmission is lowest among infants born by cesarean delivery within four hours of rupture of membranes [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/13,29\" class=\"abstract_t\">13,29</a>]. However, given that cesarean delivery does not completely eliminate the risk of HSV, asymptomatic infants who are delivered by cesarean section in women with active genital HSV lesions are managed in the same manner as those who are delivered vaginally [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/54\" class=\"abstract_t\">54</a>].</p><p>Availability of type-specific polymerase chain reaction (PCR) or culture testing of maternal genital lesions and type-specific maternal HSV serology permits more accurate characterization of the type of maternal infection (<a href=\"image.htm?imageKey=ID%2F80693\" class=\"graphic graphic_table graphicRef80693 \">table 2</a>) and, therefore, estimation of the risk of transmission [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/1,54\" class=\"abstract_t\">1,54</a>].</p><p>The 2013 American Academy of Pediatrics (AAP) clinical report on the management of asymptomatic infants born to women with active genital herpes lesions provides guidance on the evaluation and management of asymptomatic neonates in settings where type-specific HSV testing with rapid turn-around time is available [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/54\" class=\"abstract_t\">54</a>]. The approach that is described in the sections that follow is consistent with the 2013 AAP guidelines, but also provides recommendations for settings where type-specific HSV serologic testing with rapid turn-around time is not available.</p><p class=\"headingAnchor\" id=\"H421547421\"><span class=\"h2\">Monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All neonates who are born to women with active genital HSV lesions or a history of genital HSV but no active lesions at the time of delivery should be monitored for clinical evidence of HSV infection (eg, skin or scalp rashes, conjunctival lesions, irritability, sepsis, etc) (<a href=\"image.htm?imageKey=PEDS%2F67814\" class=\"graphic graphic_figure graphicRef67814 \">figure 1</a>) during the first six weeks of life [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/13\" class=\"abstract_t\">13</a>]. The infant's parents and caregivers should be educated about the signs of neonatal HSV infection.</p><p>Infants who develop clinical evidence of HSV infection should undergo full clinical and virologic evaluation (including HSV blood PCR; surface cultures; cerebrospinal fluid [CSF] HSV PCR, cell count, and chemistries; and serum alanine aminotransferase [ALT] and aspartate aminotransferase [AST]; CBC with differential and platelet count) and <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> 60 <span class=\"nowrap\">mg/kg</span> per day intravenously (IV) divided every eight hours should be administered while results of virologic evaluation are pending. (See <a href=\"#H4\" class=\"local\">'Acyclovir therapy'</a> above and <a href=\"topic.htm?path=neonatal-herpes-simplex-virus-infection-clinical-features-and-diagnosis#H67759205\" class=\"medical medical_review\">&quot;Neonatal herpes simplex virus infection: Clinical features and diagnosis&quot;, section on 'Laboratory evaluation'</a>.)</p><p class=\"headingAnchor\" id=\"H570590993\"><span class=\"h2\">Maternal history of HSV, no active lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The risk of transmission of HSV to infants born to women with a history of genital HSV but no active genital lesions at the time of delivery is low. Such infants who are asymptomatic should be monitored for neonatal HSV infection. However, we do not suggest that they be evaluated for neonatal HSV or receive prophylactic <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/13\" class=\"abstract_t\">13</a>]. (See <a href=\"#H421547421\" class=\"local\">'Monitoring'</a> above.)</p><p class=\"headingAnchor\" id=\"H510233438\"><span class=\"h2\">Maternal history of HSV, active lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The risk of transmission of HSV to infants born to women with a history of genital HSV and active genital lesions at the time of delivery is relatively low (&lt;2 percent) [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/1,13,29,54\" class=\"abstract_t\">1,13,29,54</a>]. </p><p>We suggest that the evaluation of asymptomatic infants born to women with a history of genital HSV and active genital lesions at the time of delivery include the following studies obtained at approximately 24 hours of age (whether they were delivered vaginally or by cesarean section) (<a href=\"image.htm?imageKey=PEDS%2F106124\" class=\"graphic graphic_algorithm graphicRef106124 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/13,29,54\" class=\"abstract_t\">13,29,54</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Surface cultures (ie, swabs of the mouth, nasopharynx, conjunctivae, rectum, scalp electrode site [if present], and possibly urine for viral culture)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HSV blood PCR</p><p/><p>Surface cultures obtained before 12 to 24 hours may reflect contamination during delivery, rather than infection. The sensitivity of viral cultures for detecting neonatal HSV infection in infants whose mothers were treated with antiviral medication during pregnancy is not known [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/13\" class=\"abstract_t\">13</a>].</p><p>If the surface cultures or blood HSV PCR are positive, the asymptomatic neonate should undergo full virologic evaluation (CSF for HSV PCR, cell count, chemistries; serum ALT; CBC with differential and platelet count) and be treated with <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> (60 <span class=\"nowrap\">mg/kg</span> per day IV divided every eight hours). (See <a href=\"#H4\" class=\"local\">'Acyclovir therapy'</a> above.) </p><p>We do not suggest routine prophylactic <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> for asymptomatic neonates who are born to women with a history of genital HSV and active genital lesions at the time of delivery [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/54\" class=\"abstract_t\">54</a>].</p><p>However, prophylactic <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> (60 <span class=\"nowrap\">mg/kg</span> per day IV divided every eight hours) may be warranted (after full HSV evaluation, including HSV blood PCR; surface cultures; CSF HSV PCR, cell count, and chemistries; serum ALT; CBC with differential and platelet count) for asymptomatic neonates born to women with recurrent HSV infection and additional risk factors for transmission (eg, rupture of membranes &gt;4 to 6 hours, gestation &lt;37 weeks, scalp electrode, skin lacerations) [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/1,54\" class=\"abstract_t\">1,54</a>]. If acyclovir is initiated for such patients, it may be discontinued after three to five days if the infant remains asymptomatic and HSV PCR and viral cultures are negative.</p><p class=\"headingAnchor\" id=\"H510233446\"><span class=\"h2\">No maternal history of HSV, active lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The risk of transmission of HSV to infants born to women with no history of genital HSV and active genital lesions at the time of delivery is between 25 and 60 percent [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/5,13,29\" class=\"abstract_t\">5,13,29</a>].</p><p>We suggest that the evaluation of asymptomatic infants born to women with no history of genital HSV and active genital lesions include the following studies obtained at approximately 24 hours of age (whether they were delivered vaginally or by cesarean section) (<a href=\"image.htm?imageKey=PEDS%2F106124\" class=\"graphic graphic_algorithm graphicRef106124 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/54\" class=\"abstract_t\">54</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Surface cultures (ie, swabs of the mouth, nasopharynx, conjunctivae, rectum, scalp electrode site [if present] and possibly urine for viral culture)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>HSV blood PCR</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CSF HSV PCR, cell count, chemistries</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serum ALT and AST</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CBC with differential and platelet count</p><p/><p>We also suggest sending maternal blood for type-specific HSV serology as soon as possible after delivery (if available) to more accurately characterize maternal infection (<a href=\"image.htm?imageKey=ID%2F80693\" class=\"graphic graphic_table graphicRef80693 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/54\" class=\"abstract_t\">54</a>].</p><p>Surface cultures obtained before 12 to 24 hours may reflect contamination during delivery, rather than infection. The sensitivity of viral cultures for detecting neonatal HSV infection in infants whose mothers were treated with antiviral medication during pregnancy is not known [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/13\" class=\"abstract_t\">13</a>].</p><p>We suggest that asymptomatic neonates born to women with no history of genital HSV and active genital lesions at the time of delivery be treated with <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> 60 <span class=\"nowrap\">mg/kg</span> per day IV divided every eight hours after evaluation for HSV [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/54\" class=\"abstract_t\">54</a>].</p><p>The duration of <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> is determined by the neonate's clinical status, results of the neonate's evaluation for HSV disease, and maternal HSV infection classification (<a href=\"image.htm?imageKey=PEDS%2F106124\" class=\"graphic graphic_algorithm graphicRef106124 \">algorithm 1</a>) [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/54\" class=\"abstract_t\">54</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For neonates born to women with active genital HSV lesions and no history of genital HSV infection in whom <strong>type-specific HSV serologic testing is not available</strong> who remain asymptomatic and whose HSV evaluation is negative, we suggest that prophylactic <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> be continued for 10 days.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For neonates born to women with active genital HSV lesions and no history of genital HSV infection but <strong>recurrent HSV infection </strong>(<strong>by serologic testing</strong> (<a href=\"image.htm?imageKey=ID%2F80693\" class=\"graphic graphic_table graphicRef80693 \">table 2</a>)) who remain asymptomatic, we suggest that <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> be discontinued at 48 to 72 hours if HSV PCR and viral studies are negative.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For neonates born to women with <strong>primary genital HSV</strong> infection or nonprimary <strong>first episode genital HSV</strong> infection (based on serologic testing (<a href=\"image.htm?imageKey=ID%2F80693\" class=\"graphic graphic_table graphicRef80693 \">table 2</a>)) or assumed primary or nonprimary first episode infection (based on strong clinical suspicion and discordant or unavailable genital and serologic test results) who remain asymptomatic and whose HSV evaluation is negative, we suggest that <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> be continued for 10 days.</p><p/><p>In all cases, if the infant becomes symptomatic or the HSV evaluation is abnormal (including positive PCR, culture, abnormal CSF, or serum ALT &gt;2 times the upper limit of normal), we recommend that <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> be continued for at least 14 days (for SEM infection) or at least 21 days (for CNS or disseminated disease) and that the infant undergo additional evaluation (including eye examination and neuroimaging). (See <a href=\"#H6\" class=\"local\">'Pretreatment evaluation'</a> above and <a href=\"#H4\" class=\"local\">'Acyclovir therapy'</a> above.)</p><p class=\"headingAnchor\" id=\"H29\"><span class=\"h1\">INVESTIGATIVE THERAPIES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Investigative therapies for neonatal herpes simplex virus (HSV) disease include human and humanized monoclonal antibodies directed against HSV gB and gD glycoproteins. These therapies have been beneficial in animal models of HSV disease. Studies in humans have shown that high titers of neutralizing antibodies protect neonates following perinatal HSV exposure [<a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/5\" class=\"abstract_t\">5</a>]. At present, antibody therapy for treatment or prevention of neonatal HSV is limited by the lack of an HSV hyperimmune globulin preparation and the variable amount of anti-HSV antibodies in intravenous <a href=\"topic.htm?path=immune-globulin-intravenous-subcutaneous-and-intramsucular-pediatric-drug-information\" class=\"drug drug_pediatric\">immune globulin</a> preparations.</p><p class=\"headingAnchor\" id=\"H30\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"headingAnchor\" id=\"H31\"><span class=\"h2\">Treatment</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> as the antiviral agent of choice for the treatment of all categories of neonatal herpes simplex virus (HSV) infections, including skin, eye, mouth (SEM), central nervous system (CNS), and disseminated disease (<a href=\"image.htm?imageKey=PEDS%2F106132\" class=\"graphic graphic_table graphicRef106132 \">table 1</a>) (<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>). The dose is 60 <span class=\"nowrap\">mg/kg</span> per day intravenously (IV) divided every eight hours for all forms of neonatal HSV. (See <a href=\"#H4\" class=\"local\">'Acyclovir therapy'</a> above and <a href=\"#H7\" class=\"local\">'Dose'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">Acyclovir</a> should be administered at the time neonatal HSV is suspected and continued pending results of clinical, laboratory, and imaging evaluations. Clinical features suggestive of HSV infection include mucocutaneous vesicles, seizures, aseptic meningitis, lethargy, respiratory distress, pneumonitis, thrombocytopenia, coagulopathy, hypothermia, hepatitis, sepsis-like illness, and elevated transaminases (<a href=\"image.htm?imageKey=PEDS%2F67814\" class=\"graphic graphic_figure graphicRef67814 \">figure 1</a>). Many experts recommend empiric treatment for ill-appearing neonates with fever or aseptic meningitis until results of HSV workup is known. (See <a href=\"#H5\" class=\"local\">'Indications'</a> above and <a href=\"#H67765302\" class=\"local\">'Timing'</a> above and <a href=\"topic.htm?path=neonatal-herpes-simplex-virus-infection-clinical-features-and-diagnosis#H4\" class=\"medical medical_review\">&quot;Neonatal herpes simplex virus infection: Clinical features and diagnosis&quot;, section on 'Clinical manifestations'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A comprehensive laboratory evaluation for HSV should be performed before initiation of <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> therapy. (See <a href=\"#H6\" class=\"local\">'Pretreatment evaluation'</a> above and <a href=\"topic.htm?path=neonatal-herpes-simplex-virus-infection-clinical-features-and-diagnosis#H11\" class=\"medical medical_review\">&quot;Neonatal herpes simplex virus infection: Clinical features and diagnosis&quot;, section on 'Evaluation and diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The duration of IV <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> therapy for neonatal HSV infection depends upon the pattern of illness and response to therapy. SEM disease is treated for a <strong>minimum</strong> of 14 days; CNS and disseminated disease are treated for a <strong>minimum</strong> of 21 days. (See <a href=\"#H8\" class=\"local\">'Duration of therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neonates with ocular HSV involvement should receive a topical ophthalmic solution (eg, 1 percent <a href=\"topic.htm?path=trifluridine-pediatric-drug-information\" class=\"drug drug_pediatric\">trifluridine</a>, 0.1 percent idoxuridine [iododeoxyuridine], or 0.15 percent <a href=\"topic.htm?path=ganciclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">ganciclovir</a>) in addition to systemic <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> therapy and consultation with an ophthalmologist. (See <a href=\"#H12\" class=\"local\">'Treatment of eye disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest oral <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a> suppressive therapy for six months immediately following parenteral acyclovir for all categories of neonatal HSV disease, including SEM, CNS, and disseminated disease (<a href=\"image.htm?imageKey=PEDS%2F106132\" class=\"graphic graphic_table graphicRef106132 \">table 1</a>) (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"#H11\" class=\"local\">'Oral suppressive therapy'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H32\"><span class=\"h2\">Prevention</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Strategies for prevention of intrauterine and perinatally acquired HSV infection are discussed separately. (See <a href=\"topic.htm?path=genital-herpes-simplex-virus-infection-and-pregnancy#H14708541\" class=\"medical medical_review\">&quot;Genital herpes simplex virus infection and pregnancy&quot;, section on 'Pregnancy management'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The risk of postnatal transmission of HSV can be minimized by counseling family members with active or recent history of HSV lesions (cold sores, herpetic whitlow, herpetic gingivostomatitis) or to avoid close contact with and kissing the newborn infant. (See <a href=\"#H22\" class=\"local\">'General measures'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neonates with perinatal exposure to HSV should be monitored for clinical evidence of HSV infection. Neonates who develop clinical evidence of HSV infection should undergo full virologic evaluation and be started on IV <a href=\"topic.htm?path=acyclovir-pediatric-drug-information\" class=\"drug drug_pediatric\">acyclovir</a>. (See <a href=\"#H4\" class=\"local\">'Acyclovir therapy'</a> above and <a href=\"topic.htm?path=neonatal-herpes-simplex-virus-infection-clinical-features-and-diagnosis#H67759205\" class=\"medical medical_review\">&quot;Neonatal herpes simplex virus infection: Clinical features and diagnosis&quot;, section on 'Laboratory evaluation'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The evaluation and management of asymptomatic neonates who are exposed to HSV during delivery depends upon the mother's history of genital HSV, maternal serologies for type specific HSV (if available), and the presence or absence of HSV genital lesions at the time of delivery (<a href=\"image.htm?imageKey=PEDS%2F106124\" class=\"graphic graphic_algorithm graphicRef106124 \">algorithm 1</a>). All such infants should be monitored for evidence of HSV infection (eg, skin or scalp rashes, conjunctival lesions, irritability, sepsis, etc (<a href=\"image.htm?imageKey=PEDS%2F67814\" class=\"graphic graphic_figure graphicRef67814 \">figure 1</a>)) during the first six weeks of life. (See <a href=\"#H24\" class=\"local\">'Management of the asymptomatic exposed infant'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/1\" class=\"nounderline abstract_t\">Brown ZA, Wald A, Morrow RA, et al. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA 2003; 289:203.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/2\" class=\"nounderline abstract_t\">Flagg EW, Weinstock H. Incidence of neonatal herpes simplex virus infections in the United States, 2006. Pediatrics 2011; 127:e1.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/3\" class=\"nounderline abstract_t\">Roberts S. Herpes simplex virus: incidence of neonatal herpes simplex virus, maternal screening, management during pregnancy, and HIV. Curr Opin Obstet Gynecol 2009; 21:124.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/4\" class=\"nounderline abstract_t\">Mahnert N, Roberts SW, Laibl VR, et al. The incidence of neonatal herpes infection. Am J Obstet Gynecol 2007; 196:e55.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/5\" class=\"nounderline abstract_t\">Kimberlin DW. Neonatal herpes simplex infection. Clin Microbiol Rev 2004; 17:1.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/6\" class=\"nounderline abstract_t\">Caviness AC, Demmler GJ, Swint JM, Cantor SB. Cost-effectiveness analysis of herpes simplex virus testing and treatment strategies in febrile neonates. Arch Pediatr Adolesc Med 2008; 162:665.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/7\" class=\"nounderline abstract_t\">Davis KL, Shah SS, Frank G, Eppes SC. Why are young infants tested for herpes simplex virus? Pediatr Emerg Care 2008; 24:673.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/8\" class=\"nounderline abstract_t\">Ambroggio L, Lorch SA, Mohamad Z, et al. Congenital anomalies and resource utilization in neonates infected with herpes simplex virus. Sex Transm Dis 2009; 36:680.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/9\" class=\"nounderline abstract_t\">Nagamori T, Koyano S, Asai Y, et al. Sequential changes in pathophysiology of systemic inflammatory response in a disseminated neonatal herpes simplex virus (HSV) infection. J Clin Virol 2012; 53:265.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/10\" class=\"nounderline abstract_t\">Egawa H, Inomata Y, Nakayama S, et al. Fulminant hepatic failure secondary to herpes simplex virus infection in a neonate: A case report of successful treatment with liver transplantation and perioperative acyclovir. Liver Transpl Surg 1998; 4:513.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/11\" class=\"nounderline abstract_t\">Maeba S, Hasegawa S, Shimomura M, et al. Successful Treatment of Corticosteroid with Antiviral Therapy for a Neonatal Liver Failure with Disseminated Herpes Simplex Virus Infection. AJP Rep 2015; 5:e089.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/12\" class=\"nounderline abstract_t\">Yamada K, Yamamoto Y, Uchiyama A, et al. Successful treatment of neonatal herpes simplex-type 1 infection complicated by hemophagocytic lymphohistiocytosis and acute liver failure. Tohoku J Exp Med 2008; 214:1.</a></li><li class=\"breakAll\">American Academy of Pediatrics. Herpes simplex. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.432.</li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/14\" class=\"nounderline abstract_t\">Kimberlin DW, Lin CY, Jacobs RF, et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 2001; 108:230.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/15\" class=\"nounderline abstract_t\">Whitley R, Arvin A, Prober C, et al. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med 1991; 324:444.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/16\" class=\"nounderline abstract_t\">Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/17\" class=\"nounderline abstract_t\">Jones CA, Walker KS, Badawi N. Antiviral agents for treatment of herpes simplex virus infection in neonates. Cochrane Database Syst Rev 2009; :CD004206.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/18\" class=\"nounderline abstract_t\">Whitley RJ, Nahmias AJ, Soong SJ, et al. Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics 1980; 66:495.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/19\" class=\"nounderline abstract_t\">Kimberlin DW. Herpes simplex virus infections of the newborn. Semin Perinatol 2007; 31:19.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/20\" class=\"nounderline abstract_t\">Whitley RJ, Corey L, Arvin A, et al. Changing presentation of herpes simplex virus infection in neonates. J Infect Dis 1988; 158:109.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/21\" class=\"nounderline abstract_t\">Caviness AC, Demmler GJ, Almendarez Y, Selwyn BJ. The prevalence of neonatal herpes simplex virus infection compared with serious bacterial illness in hospitalized neonates. J Pediatr 2008; 153:164.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/22\" class=\"nounderline abstract_t\">Long SS. In defense of empiric acyclovir therapy in certain neonates. J Pediatr 2008; 153:157.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/23\" class=\"nounderline abstract_t\">Kimberlin DW. When should you initiate acyclovir therapy in a neonate? J Pediatr 2008; 153:155.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/24\" class=\"nounderline abstract_t\">Long SS, Pool TE, Vodzak J, et al. Herpes simplex virus infection in young infants during 2 decades of empiric acyclovir therapy. Pediatr Infect Dis J 2011; 30:556.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/25\" class=\"nounderline abstract_t\">Shah SS, Aronson PL, Mohamad Z, Lorch SA. Delayed acyclovir therapy and death among neonates with herpes simplex virus infection. Pediatrics 2011; 128:1153.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/26\" class=\"nounderline abstract_t\">Mej&iacute;as A, Bustos R, Ardura MI, et al. Persistence of herpes simplex virus DNA in cerebrospinal fluid of neonates with herpes simplex virus encephalitis. J Perinatol 2009; 29:290.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/27\" class=\"nounderline abstract_t\">Kimura H, Futamura M, Kito H, et al. Detection of viral DNA in neonatal herpes simplex virus infections: frequent and prolonged presence in serum and cerebrospinal fluid. J Infect Dis 1991; 164:289.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/28\" class=\"nounderline abstract_t\">Troendle-Atkins J, Demmler GJ, Buffone GJ. Rapid diagnosis of herpes simplex virus encephalitis by using the polymerase chain reaction. J Pediatr 1993; 123:376.</a></li><li class=\"breakAll\">Gutierrez K, Pinsky B, Arvin AM. Herpes simplex viruses 1 and 2. In: Feigin and Cherry&rsquo;s Textbook of Pediatric Infectious Diseases, 7th, Cherry JD, Harrison GJ, Kaplan SL, et al (Eds), Elsevier Saunders, Philadelphia 2014. p.1933.</li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/30\" class=\"nounderline abstract_t\">Melvin AJ, Mohan KM, Schiffer JT, et al. Plasma and cerebrospinal fluid herpes simplex virus levels at diagnosis and outcome of neonatal infection. J Pediatr 2015; 166:827.</a></li><li class=\"breakAll\">Current Drug Shortages. US Food and Drug Administration. www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm (Accessed on November 28, 2012).</li><li class=\"breakAll\">Shortage of intravenous acyclovir. Red Book Online Special Alert - November 28, 2012.</li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/33\" class=\"nounderline abstract_t\">Kimberlin DW. Ganciclovir may be used during intravenous acyclovir shortage. AAP News 2009; 30:10.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/34\" class=\"nounderline abstract_t\">Kimberlin DW, Whitley RJ, Wan W, et al. Oral acyclovir suppression and neurodevelopment after neonatal herpes. N Engl J Med 2011; 365:1284.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/35\" class=\"nounderline abstract_t\">Fish DN, Vidaurri VA, Deeter RG. Stability of valacyclovir hydrochloride in extemporaneously prepared oral liquids. Am J Health Syst Pharm 1999; 56:1957.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/36\" class=\"nounderline abstract_t\">Bomgaars L, Thompson P, Berg S, et al. Valacyclovir and acyclovir pharmacokinetics in immunocompromised children. Pediatr Blood Cancer 2008; 51:504.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/37\" class=\"nounderline abstract_t\">Kimberlin DW, Jacobs RF, Weller S, et al. Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age. Clin Infect Dis 2010; 50:221.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/38\" class=\"nounderline abstract_t\">Fonseca-Aten M, Messina AF, Jafri HS, S&aacute;nchez PJ. Herpes simplex virus encephalitis during suppressive therapy with acyclovir in a premature infant. Pediatrics 2005; 115:804.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/39\" class=\"nounderline abstract_t\">Kimberlin D, Powell D, Gruber W, et al. Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. Pediatr Infect Dis J 1996; 15:247.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/40\" class=\"nounderline abstract_t\">Kimberlin DW, Lin CY, Jacobs RF, et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics 2001; 108:223.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/41\" class=\"nounderline abstract_t\">Whitley R, Arvin A, Prober C, et al. Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med 1991; 324:450.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/42\" class=\"nounderline abstract_t\">Verma A, Dhawan A, Zuckerman M, et al. Neonatal herpes simplex virus infection presenting as acute liver failure: prevalent role of herpes simplex virus type I. J Pediatr Gastroenterol Nutr 2006; 42:282.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/43\" class=\"nounderline abstract_t\">Twagira M, Hadzic N, Smith M, et al. Disseminated neonatal herpes simplex virus (HSV) type 2 infection diagnosed by HSV DNA detection in blood and successfully managed by liver transplantation. Eur J Pediatr 2004; 163:166.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/44\" class=\"nounderline abstract_t\">Westerberg BD, Atashband S, Kozak FK. A systematic review of the incidence of sensorineural hearing loss in neonates exposed to Herpes simplex virus (HSV). Int J Pediatr Otorhinolaryngol 2008; 72:931.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/45\" class=\"nounderline abstract_t\">Grose C. Acute retinal necrosis caused by herpes simplex virus type 2 in children: reactivation of an undiagnosed latent neonatal herpes infection. Semin Pediatr Neurol 2012; 19:115.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/46\" class=\"nounderline abstract_t\">Landry ML, Mullangi P, Nee P, Klein BR. Herpes simplex virus type 2 acute retinal necrosis 9 years after neonatal herpes. J Pediatr 2005; 146:836.</a></li><li class=\"breakAll\">American Academy of Pediatrics. Transmission of infectious agents via human milk. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.128.</li><li class=\"breakAll\">Gutierrez KM, Whitley RJ, Arvin AM. Herpes simplex virus infections. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington JS, Klein JO, Wilson CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.813.</li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/49\" class=\"nounderline abstract_t\">Corey L, Wald A. Maternal and neonatal herpes simplex virus infections. N Engl J Med 2009; 361:1376.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/50\" class=\"nounderline abstract_t\">Overall JC Jr. Empiric therapy with acyclovir for suspected neonatal herpes simplex infection. Pediatr Infect Dis J 1989; 8:808.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/51\" class=\"nounderline abstract_t\">Overall JC Jr. Herpes simplex virus infection of the fetus and newborn. Pediatr Ann 1994; 23:131.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/52\" class=\"nounderline abstract_t\">Prober CG, Corey L, Brown ZA, et al. The management of pregnancies complicated by genital infections with herpes simplex virus. Clin Infect Dis 1992; 15:1031.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/53\" class=\"nounderline abstract_t\">Scott LL. Perinatal herpes: current status and obstetric management strategies. Pediatr Infect Dis J 1995; 14:827.</a></li><li><a href=\"https://www.uptodate.com/contents/neonatal-herpes-simplex-virus-infection-management-and-prevention/abstract/54\" class=\"nounderline abstract_t\">Kimberlin DW, Baley J, Committee on infectious diseases, Committee on fetus and newborn. Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. Pediatrics 2013; 131:e635.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 6040 Version 32.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H30\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">OVERVIEW</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Supportive measures</a></li></ul></li><li><a href=\"#H4\" id=\"outline-link-H4\">ACYCLOVIR THERAPY</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">Indications</a></li><li><a href=\"#H67765302\" id=\"outline-link-H67765302\">Timing</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Pretreatment evaluation</a></li><li><a href=\"#H443693524\" id=\"outline-link-H443693524\">Initial treatment</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">- Dose</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">- Duration of therapy</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">- Adverse effects</a></li><li><a href=\"#H443693633\" id=\"outline-link-H443693633\">- Monitoring</a></li><li><a href=\"#H67767244\" id=\"outline-link-H67767244\">- IV acyclovir not available</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">Oral suppressive therapy</a></li><li><a href=\"#H443693101\" id=\"outline-link-H443693101\">Treatment of recurrences</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Treatment of eye disease</a></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">OUTCOME</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">Disseminated disease</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">CNS disease</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Skin, eye, and mouth disease</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">Cutaneous recurrence</a></li></ul></li><li><a href=\"#H20\" id=\"outline-link-H20\">LONG-TERM FOLLOW-UP</a></li><li><a href=\"#H21\" id=\"outline-link-H21\">PREVENTION</a><ul><li><a href=\"#H22\" id=\"outline-link-H22\">General measures</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">Vaccine</a></li></ul></li><li><a href=\"#H24\" id=\"outline-link-H24\">MANAGEMENT OF THE ASYMPTOMATIC EXPOSED INFANT</a><ul><li><a href=\"#H421546997\" id=\"outline-link-H421546997\">Overview</a></li><li><a href=\"#H421547421\" id=\"outline-link-H421547421\">Monitoring</a></li><li><a href=\"#H570590993\" id=\"outline-link-H570590993\">Maternal history of HSV, no active lesions</a></li><li><a href=\"#H510233438\" id=\"outline-link-H510233438\">Maternal history of HSV, active lesions</a></li><li><a href=\"#H510233446\" id=\"outline-link-H510233446\">No maternal history of HSV, active lesions</a></li></ul></li><li><a href=\"#H29\" id=\"outline-link-H29\">INVESTIGATIVE THERAPIES</a></li><li><a href=\"#H30\" id=\"outline-link-H30\">SUMMARY AND RECOMMENDATIONS</a><ul><li><a href=\"#H31\" id=\"outline-link-H31\">Treatment</a></li><li><a href=\"#H32\" id=\"outline-link-H32\">Prevention</a></li></ul></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/6040|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/106124\" class=\"graphic graphic_algorithm\">- Management of neonates at risk for HSV</a></li></ul></li><li><div id=\"PEDS/6040|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/67814\" class=\"graphic graphic_figure\">- Neonatal HSV SSx</a></li></ul></li><li><div id=\"PEDS/6040|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/75059\" class=\"graphic graphic_picture\">- Neonatal herpes simplex virus neck vesicles</a></li><li><a href=\"image.htm?imageKey=PEDS/56041\" class=\"graphic graphic_picture\">- Neonatal HSV scalp vesicles</a></li><li><a href=\"image.htm?imageKey=PEDS/78598\" class=\"graphic graphic_picture\">- Neonatal herpes simplex virus eye vesicles</a></li></ul></li><li><div id=\"PEDS/6040|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/106132\" class=\"graphic graphic_table\">- Neonatal HSV diseases</a></li><li><a href=\"image.htm?imageKey=ID/80693\" class=\"graphic graphic_table\">- Clinical designation of genital herpes simplex virus infection</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acyclovir-an-overview\" class=\"medical medical_review\">Acyclovir: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-herpes-simplex-virus-type-1-infection\" class=\"medical medical_review\">Clinical manifestations and diagnosis of herpes simplex virus type 1 infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=developmental-behavioral-surveillance-and-screening-in-primary-care\" class=\"medical medical_review\">Developmental-behavioral surveillance and screening in primary care</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=disseminated-intravascular-coagulation-in-infants-and-children\" class=\"medical medical_review\">Disseminated intravascular coagulation in infants and children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fluid-and-electrolyte-therapy-in-newborns\" class=\"medical medical_review\">Fluid and electrolyte therapy in newborns</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=genital-herpes-simplex-virus-infection-and-pregnancy\" class=\"medical medical_review\">Genital herpes simplex virus infection and pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hearing-impairment-in-children-evaluation\" class=\"medical medical_review\">Hearing impairment in children: Evaluation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=herpetic-gingivostomatitis-in-young-children\" class=\"medical medical_review\">Herpetic gingivostomatitis in young children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection\" class=\"medical medical_review\">Infection prevention: Precautions for preventing transmission of infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-and-outcome-of-neonatal-hypoglycemia\" class=\"medical medical_review\">Management and outcome of neonatal hypoglycemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-and-outcome-of-sepsis-in-term-and-late-preterm-infants\" class=\"medical medical_review\">Management and outcome of sepsis in term and late preterm infants</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mechanical-ventilation-in-neonates\" class=\"medical medical_review\">Mechanical ventilation in neonates</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neonatal-herpes-simplex-virus-infection-clinical-features-and-diagnosis\" class=\"medical medical_review\">Neonatal herpes simplex virus infection: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=noninvasive-oxygen-delivery-and-oxygen-monitoring-in-the-newborn\" class=\"medical medical_review\">Noninvasive oxygen delivery and oxygen monitoring in the newborn</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-enteral-nutrition-in-infants-and-children\" class=\"medical medical_review\">Overview of enteral nutrition in infants and children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=parenteral-nutrition-in-infants-and-children\" class=\"medical medical_review\">Parenteral nutrition in infants and children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=septic-shock-in-children-ongoing-management-after-resuscitation\" class=\"medical medical_review\">Septic shock in children: Ongoing management after resuscitation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=septic-shock-in-children-rapid-recognition-and-initial-resuscitation-first-hour\" class=\"medical medical_review\">Septic shock in children: Rapid recognition and initial resuscitation (first hour)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prognosis-of-myocarditis-in-children\" class=\"medical medical_review\">Treatment and prognosis of myocarditis in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-neonatal-seizures\" class=\"medical medical_review\">Treatment of neonatal seizures</a></li></ul></div></div>","javascript":null}